Ella X. Du
Education
M.A., environmental economics and policy analysis, Yale School of Forestry & Environmental Studies; B.A., economics, and B.S., atmospheric science, Peking University
Summary of Experience
Ms. Du specializes in health economics and outcomes research (HEOR). She has extensive experience in applying advanced biostatistical and epidemiological methods to address real-world challenges for life science companies. Ms. Du’s expertise spans real-world data generation using administrative claims, medical chart reviews, surveys, and disease registries; comparative effectiveness studies using clinical trial data; economic modeling studies such as budget impact analysis, cost-effectiveness studies, and modeling related to value-based contracting; and survey studies, including discrete choice method studies. She has supported health care decision-making across various disease areas, including oncology, hematology, rheumatology, dermatology, and endocrinology. Ms. Du’s work is widely published in peer-reviewed journals and presented at clinical and economic research conferences.
-
Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting
Gynecologic Oncology Reports, 2024
2024Rimel BJ, Chase DM, Perhanidis J, Ghazarian AA, Du EX, Wang T, Song J, Golembesky AK, Hurteau JA, Kalilani L, Salani R, Monk BJ
-
-
Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
Oncology and Therapy, 2024
2024Du EX, Betts KA, Wang T, Kitchen SA, He X, Yin X, Guttenplan SB, Beauchamp K, Delgado A, Rosenblatt L
-
Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment
PharmacoEconomics - Open, 2024
2024Chen Y, Du EX, Sundar M, Betts KA, Yin X, Eiffert S, Beauchamp K, Delgado A, Rosenblatt L
-
A Matching-Adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
European Urology Oncology, 2023
2023McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Tejo VD, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C
-
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
Cancer Immunology, Immunotherapy, 2022
2022Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN
-
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
Clinical Drug Investigation, 2022
2022Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Huo S, Del Tejo V, Du EX, Yang X, Betts KA, Choueiri TK, McGregor B
-
Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
Future Oncology, 2022
2022Geynisman DM, Du EX, Yang X, Sendhil SR, Tejo VD, Betts KA, Huo S
-
A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
Rheumatology and Therapy, 2021
2021 -
Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era
Current Medical Research and Opinion, 2021
2021 -
US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
Journal of Comparative Effectiveness Research, 2020
2020Betts KA, Thuresson PO, Felizzi F, Du EX, Dieye I, Li J, Schulz M, Masaquel AS
-
Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
Advances in Therapy, 2019
2019Freeman M, Betts KA, Jiang S, Du EX, Gupte-Singh K, Lu Y, Rao S, Shoushtari AN
-
Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis
Advances in Therapy, 2016 05; 33(5): 807-823. e-pub ahead of print 2016/04/17
2016
-
March 25, 2025
-
April 11, 2024
-
February 1, 2024
-
October 23, 2023